Alirocumab-话题@MedSci - 梅斯（MedSci）

#Alirocumab#

17篇内容 | 1210人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378614, encodeId=b0a813e86142e, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=Eur Heart J：Alirocumab 对高龄冠心病患者预后的影响研究, objectType=article, longId=196733, objectId=d89c196e3356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89c196e3356, replyNumber=0, likeNumber=67, createdTime=2020-07-01, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89c196e3356, moduleTitle=Eur Heart J：Alirocumab 对高龄冠心病患者预后的影响研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d89c196e3356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378613, encodeId=7fae13e8613eb, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=Circulation：高PRS的CAD患者可从alirocumab治疗中明显获益, objectType=article, longId=189139, objectId=6dd118913900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dd118913900, replyNumber=0, likeNumber=65, createdTime=2020-03-03, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dd118913900, moduleTitle=Circulation：高PRS的CAD患者可从alirocumab治疗中明显获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6dd118913900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378612, encodeId=b1d113e8612d6, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=JACC：Alirocumab 可以降低急性冠脉综合征患者心血管风险, objectType=article, longId=186315, objectId=2ff1186315fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ff1186315fb, replyNumber=0, likeNumber=114, createdTime=2020-01-17, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ff1186315fb, moduleTitle=JACC：Alirocumab 可以降低急性冠脉综合征患者心血管风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2ff1186315fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378611, encodeId=068213e861149, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=Eur Heart J：Alirocumab对急性冠脉综合征患者心血管预后的影响, objectType=article, longId=183124, objectId=8b5118312428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b5118312428, replyNumber=0, likeNumber=111, createdTime=2019-11-19, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b5118312428, moduleTitle=Eur Heart J：Alirocumab对急性冠脉综合征患者心血管预后的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8b5118312428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378610, encodeId=3e3413e86104f, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=Lancet Diabetes Endo：alirocumab可大幅降低新近ACS患者后继心血管事件风险, objectType=article, longId=174849, objectId=fe261e484957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe261e484957, replyNumber=0, likeNumber=87, createdTime=2019-07-06, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe261e484957, moduleTitle=Lancet Diabetes Endo：alirocumab可大幅降低新近ACS患者后继心血管事件风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fe261e484957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378609, encodeId=088013e860915, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=欧盟批准Alirocumab用于降低成人动脉粥样硬化性心脏病的心血管风险, objectType=article, longId=162522, objectId=c24716252292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24716252292, replyNumber=0, likeNumber=77, createdTime=2019-03-19, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24716252292, moduleTitle=欧盟批准Alirocumab用于降低成人动脉粥样硬化性心脏病的心血管风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c24716252292)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378608, encodeId=da9913e860821, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新, objectType=article, longId=160533, objectId=43881605336e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43881605336e, replyNumber=0, likeNumber=110, createdTime=2019-02-21, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43881605336e, moduleTitle=临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=43881605336e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378607, encodeId=dd8313e86077e, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=Alirocumab联合他汀类药物治疗可降低糖尿病患者的心脏事件风险, objectType=article, longId=142040, objectId=97df142040ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97df142040ce, replyNumber=0, likeNumber=72, createdTime=2018-07-02, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97df142040ce, moduleTitle=Alirocumab联合他汀类药物治疗可降低糖尿病患者的心脏事件风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=97df142040ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378606, encodeId=ee4913e86067b, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=Diabetic Med：alirocumab在糖尿病前期患者和基线血糖正常患者中的疗效和安全性？, objectType=article, longId=133907, objectId=3fb713390ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb713390ef2, replyNumber=0, likeNumber=110, createdTime=2018-04-01, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb713390ef2, moduleTitle=Diabetic Med：alirocumab在糖尿病前期患者和基线血糖正常患者中的疗效和安全性？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3fb713390ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378605, encodeId=d23713e860540, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=Diabetes Obes Metab：Alirocumab对代谢综合征和无糖尿病个体脂质和脂蛋白的影响！, objectType=article, longId=131365, objectId=0e4913136563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e4913136563, replyNumber=0, likeNumber=69, createdTime=2018-03-05, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e4913136563, moduleTitle=Diabetes Obes Metab：Alirocumab对代谢综合征和无糖尿病个体脂质和脂蛋白的影响！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0e4913136563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=新型降脂药Alirocumab获FDA批准和欧洲CHMP批准建议, objectType=article, longId=54169, objectId=cbdb541696e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbdb541696e, replyNumber=0, likeNumber=70, createdTime=2015-07-31, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbdb541696e, moduleTitle=新型降脂药Alirocumab获FDA批准和欧洲CHMP批准建议, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cbdb541696e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378603, encodeId=491813e860384, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平, objectType=article, longId=49564, objectId=fcff495646e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcff495646e, replyNumber=0, likeNumber=76, createdTime=2015-04-19, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcff495646e, moduleTitle=NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fcff495646e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378602, encodeId=40a213e86020e, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=NEJM：新药Alirocumab能够安全降脂, objectType=article, longId=48257, objectId=1a9e4825ee4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a9e4825ee4, replyNumber=0, likeNumber=116, createdTime=2015-03-18, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a9e4825ee4, moduleTitle=NEJM：新药Alirocumab能够安全降脂, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1a9e4825ee4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378601, encodeId=d6a313e860138, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia, objectType=article, longId=42968, objectId=df2042968c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2042968c5, replyNumber=0, likeNumber=77, createdTime=2014-11-23, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2042968c5, moduleTitle=赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df2042968c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378600, encodeId=790713e86001f, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点, objectType=article, longId=38618, objectId=b1903861805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1903861805, replyNumber=0, likeNumber=78, createdTime=2014-08-06, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1903861805, moduleTitle=赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b1903861805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378599, encodeId=459113e85998e, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=FDA评估alirocumab神经认知副作用, objectType=article, longId=32438, objectId=56d73243863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56d73243863, replyNumber=0, likeNumber=82, createdTime=2014-03-28, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56d73243863, moduleTitle=FDA评估alirocumab神经认知副作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=56d73243863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378598, encodeId=f9fa13e85988a, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, objectTitle=FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大, objectType=article, longId=31688, objectId=117b31688b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117b31688b0, replyNumber=0, likeNumber=84, createdTime=2014-03-12, rootId=0, userName=30397604, userId=a691420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117b31688b0, moduleTitle=FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=117b31688b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Alirocumab

2020-05-29

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

Eur Heart J：Alirocumab 对高龄冠心病患者预后的影响研究

2020-07-01

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

Circulation：高PRS的CAD患者可从alirocumab治疗中明显获益

2020-03-03

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

JACC：Alirocumab 可以降低急性冠脉综合征患者心血管风险

2020-01-17

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

Eur Heart J：Alirocumab对急性冠脉综合征患者心血管预后的影响

2019-11-19

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

Lancet Diabetes Endo：alirocumab可大幅降低新近ACS患者后继心血管事件风险

2019-07-06

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

欧盟批准Alirocumab用于降低成人动脉粥样硬化性心脏病的心血管风险

2019-03-19

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新

2019-02-21

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

Alirocumab联合他汀类药物治疗可降低糖尿病患者的心脏事件风险

2018-07-02

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

Diabetic Med：alirocumab在糖尿病前期患者和基线血糖正常患者中的疗效和安全性？

2018-04-01

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

Diabetes Obes Metab：Alirocumab对代谢综合征和无糖尿病个体脂质和脂蛋白的影响！

2018-03-05

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

新型降脂药Alirocumab获FDA批准和欧洲CHMP批准建议

2015-07-31

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平

2015-04-19

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

NEJM：新药Alirocumab能够安全降脂

2015-03-18

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia

2014-11-23

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点

2014-08-06

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

FDA评估alirocumab神经认知副作用

2014-03-28

30397604 (审核中...)

前往app查看评论内容

#Alirocumab#

FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大

2014-03-12

科室
- - 订阅+
  - 更多科室
工具
服务